Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Author:

Herbst Roy S.1,Giaccone Giuseppe1,de Marinis Filippo1,Reinmuth Niels1,Vergnenegre Alain1,Barrios Carlos H.1,Morise Masahiro1,Felip Enriqueta1,Andric Zoran1,Geater Sarayut1,Özgüroğlu Mustafa1,Zou Wei1,Sandler Alan1,Enquist Ida1,Komatsubara Kimberly1,Deng Yu1,Kuriki Hiroshi1,Wen Xiaohui1,McCleland Mark1,Mocci Simonetta1,Jassem Jacek1,Spigel David R.1

Affiliation:

1. From the Yale School of Medicine, New Haven, CT (R.S.H.); Weill Cornell Medical Center, New York (G.G.); the European Institute of Oncology, IRCCS, Milan (F.M.); Asklepios Lung Clinic, Munich-Gauting, Germany (N.R.); University Hospital Limoges, Limoges, France (A.V.); Centro de Pesquisa Clínica, Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil (C.H.B.); Nagoya University Graduate School of Medicine, Aichi, Japan (M. Morise); Vall d’Hebron University...

Funder

F. Hoffmann-La Roche

Publisher

Massachusetts Medical Society

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3